ImmunityBio, Inc. cash flow to debt ratio of -34.73% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

ImmunityBio, Inc.'s free cash flow has increased -22.44% from $-398.12M last year to $-308.78M, signaling increasing performance

ImmunityBio, Inc.'s debt to equity ratio is -0.04, signaling that the company spent its equity and risk bankruptcy.

ImmunityBio, Inc.'s debt to equity ratio is -0.04, signaling that the company spent its equity and risk bankruptcy.

ImmunityBio, Inc. has negative EBITDA, making leverage ratio unreliable

ImmunityBio, Inc.'s interest coverage ratio is -3.02, which means that the company struggles to meet interest obligations, signaling financial risk.

ImmunityBio, Inc.'s profit margin has increased (-78.66%) in the last year from -2.80K% to -598.56%, signaling increasing performance

ImmunityBio, Inc.'s short-term assets of $314.88M exceed its short-term liabilities of $61.75M

ImmunityBio, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

ImmunityBio, Inc.'s return on equity of 135.03%, is higher than 15.00%, indicating good performance

ImmunityBio, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

ImmunityBio, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

ImmunityBio, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

ImmunityBio, Inc. has negative free cash flow, indicating cash burn

ImmunityBio, Inc.'s yearly earnings has increased -15.03% since last year from $-413.56M to $-351.40M, signaling increasing performance

ImmunityBio, Inc.'s yearly revenue has increased 668.31% since last year from $14.74M to $113.29M, signaling increasing performance

ROIC -45.01% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

ImmunityBio, Inc.'s 3-year revenue CAGR of 678.62% is positive, indicating growing revenue over the past 3 years

ImmunityBio, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

ImmunityBio, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

ImmunityBio, Inc. has insufficient data to evaluate this check.

ImmunityBio, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

ImmunityBio, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

ImmunityBio, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

ImmunityBio, Inc. is overvalued relative to its fair value price of -842.93 based on Earnings Fair Value model

ImmunityBio, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

ImmunityBio, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

ImmunityBio, Inc. has a price-to-sales ratio of 47.44x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue